Correlation Between Palatin Technologies and Estrella Immunopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Palatin Technologies and Estrella Immunopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Palatin Technologies and Estrella Immunopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Palatin Technologies and Estrella Immunopharma, you can compare the effects of market volatilities on Palatin Technologies and Estrella Immunopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Palatin Technologies with a short position of Estrella Immunopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Palatin Technologies and Estrella Immunopharma.

Diversification Opportunities for Palatin Technologies and Estrella Immunopharma

-0.33
  Correlation Coefficient

Very good diversification

The 3 months correlation between Palatin and Estrella is -0.33. Overlapping area represents the amount of risk that can be diversified away by holding Palatin Technologies and Estrella Immunopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Estrella Immunopharma and Palatin Technologies is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Palatin Technologies are associated (or correlated) with Estrella Immunopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Estrella Immunopharma has no effect on the direction of Palatin Technologies i.e., Palatin Technologies and Estrella Immunopharma go up and down completely randomly.

Pair Corralation between Palatin Technologies and Estrella Immunopharma

Considering the 90-day investment horizon Palatin Technologies is expected to under-perform the Estrella Immunopharma. But the stock apears to be less risky and, when comparing its historical volatility, Palatin Technologies is 1.17 times less risky than Estrella Immunopharma. The stock trades about -0.09 of its potential returns per unit of risk. The Estrella Immunopharma is currently generating about 0.09 of returns per unit of risk over similar time horizon. If you would invest  97.00  in Estrella Immunopharma on September 15, 2024 and sell it today you would earn a total of  26.00  from holding Estrella Immunopharma or generate 26.8% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Palatin Technologies  vs.  Estrella Immunopharma

 Performance 
       Timeline  
Palatin Technologies 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Palatin Technologies has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Estrella Immunopharma 

Risk-Adjusted Performance

6 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Estrella Immunopharma are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat inconsistent essential indicators, Estrella Immunopharma sustained solid returns over the last few months and may actually be approaching a breakup point.

Palatin Technologies and Estrella Immunopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Palatin Technologies and Estrella Immunopharma

The main advantage of trading using opposite Palatin Technologies and Estrella Immunopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Palatin Technologies position performs unexpectedly, Estrella Immunopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Estrella Immunopharma will offset losses from the drop in Estrella Immunopharma's long position.
The idea behind Palatin Technologies and Estrella Immunopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Other Complementary Tools

Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Stocks Directory
Find actively traded stocks across global markets